Your browser doesn't support javascript.
loading
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand, Philippe; Rodig, Scott; Melnichenko, Vladimir; Thieblemont, Catherine; Bouabdallah, Kamal; Tumyan, Gayane; Özcan, Muhit; Portino, Sergio; Fogliatto, Laura; Caballero, Maria D; Walewski, Jan; Gulbas, Zafer; Ribrag, Vincent; Christian, Beth; Perini, Guilherme Fleury; Salles, Gilles; Svoboda, Jakub; Zain, Jasmine; Patel, Sanjay; Chen, Pei-Hsuan; Ligon, Azra H; Ouyang, Jing; Neuberg, Donna; Redd, Robert; Chatterjee, Arkendu; Balakumaran, Arun; Orlowski, Robert; Shipp, Margaret; Zinzani, Pier Luigi.
Afiliação
  • Armand P; Dana-Farber Cancer Institute, Boston, MA.
  • Rodig S; Dana-Farber Cancer Institute, Boston, MA.
  • Melnichenko V; Pirogov National Medical Surgical Center, Moscow, Russia.
  • Thieblemont C; Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
  • Bouabdallah K; Hôpital Haut-Levêque, Pessac, France.
  • Tumyan G; N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Özcan M; Ankara University Medical School, Ankara, Turkey.
  • Portino S; Clinica Alemana de Santiago, Santiago, Chile.
  • Fogliatto L; Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
  • Caballero MD; Hospital Clínico de Salamanca, Salamanca, Spain.
  • Walewski J; Maria Sklodowska-Curie Institute Oncology Center, Warszawa, Poland.
  • Gulbas Z; Anadolu Medical Center, Gebze, Turkey.
  • Ribrag V; Institut Gustave Roussy, Paris, France.
  • Christian B; The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Perini GF; Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
  • Salles G; Universite Claude Bernard Lyon, Lyon, France.
  • Svoboda J; University of Pennsylvania, Philadelphia, PA.
  • Zain J; City of Hope, Duarte, CA.
  • Patel S; Brigham & Women's Hospital, Boston, MA.
  • Chen PH; Dana-Farber Cancer Institute, Boston, MA.
  • Ligon AH; Brigham & Women's Hospital, Boston, MA.
  • Ouyang J; Dana-Farber Cancer Institute, Boston, MA.
  • Neuberg D; Dana-Farber Cancer Institute, Boston, MA.
  • Redd R; Dana-Farber Cancer Institute, Boston, MA.
  • Chatterjee A; Merck & Co, Kenilworth, NJ.
  • Balakumaran A; Merck & Co, Kenilworth, NJ.
  • Orlowski R; Merck & Co, Kenilworth, NJ.
  • Shipp M; Dana-Farber Cancer Institute, Boston, MA.
  • Zinzani PL; Institute of Hematology, Seràgnoli University of Bologna, Bologna, Italy.
J Clin Oncol ; 37(34): 3291-3299, 2019 12 01.
Article em En | MEDLINE | ID: mdl-31609651
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Neoplasias do Mediastino / Recidiva Local de Neoplasia País/Região como assunto: America do norte / America do sul / Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Marrocos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Resistencia a Medicamentos Antineoplásicos / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Neoplasias do Mediastino / Recidiva Local de Neoplasia País/Região como assunto: America do norte / America do sul / Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Marrocos